Heterozygous Germline ATM Mutations Do Not Contribute to Radiation-Associated Malignancies After Hodgkin's Disease PURPOSE: To examine the safety, efficacy, costs, and impact on quality of life of ...
MIAMI, June 22, 2026 /PRNewswire/ -- PorTal Access, Inc., an innovative medical device company advancing vascular access technologies, today announced that the U.S. Food and Drug Administration (FDA) ...
Accelerating innovation in outcomes and quality-of-care research through integrating clinical databases: Pediatric oncology experience in Egypt. This is an ASCO Meeting Abstract from the 2014 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results